Table 2.
Diseases potentially linked to the use of lopinavir/ritonavir as fixed combination, or when regarded as separate substances in the CTD database (SetAnalyzer CTD tool, p-value: 0.01).
| Disease | Disease Categories | Corrected p-value |
Genes (Number) | Annotated Genes | |
|---|---|---|---|---|---|
| Lopinavir/Ritonavir fixed combination | Cardiovascular Diseases | Cardiovascular disease | 3.95E-15 | 13 | APOA1,APOA4,APOB,APOC3,CCL2,CDKN1A,CXCL1,CXCL2,CXCL3, CXCL8,ICAM1,IL6,PTGS2 |
| Lung Diseases | Respiratory tract disease | 1.24E-13 | 11 | APOA1,APOC3,CCL2,CDKN1A|CXCL1,CXCL2,CXCL8,ICAM1,IL6,PTGS2,PTX3 | |
| Reperfusion Injury | Cardiovascular disease Pathology (process) |
1.44E-13 | 8 | CCL2,CDKN1A,CXCL1,CXCL2,CXCL8,ICAM1,IL6,PTGS2 | |
| Myocardial Ischemia | Cardiovascular disease | 1.59E-12 | 9 | APOA1,APOB,APOC3,CCL2,CXCL2,CXCL8,ICAM1,IL6,PTGS2 | |
| Arteriosclerosis | Cardiovascular disease | 4.92E-12 | 7 | APOA1,APOA4,APOC3,CCL2,ICAM1,IL6,PTGS2 | |
| Hypersensitivity | Immune system disease | 2.58E-11 | 8 | APOA1,APOC3,CCL2,CXCL1,CXCL2,ICAM1,IL6,PTGS2 | |
| Inflammation | Pathology (process) | 5.72E-11 | 7 | APOA1,CCL2,CXCL2,CXCL8,ICAM1,IL6,PTGS2 | |
| Stroke | Cardiovascular disease Nervous system disease |
2.93E-10 | 6 | APOA1,CCL2,CXCL2,ICAM1,IL6,PTGS2 | |
| Hyperlipidemias | Metabolic disease | 6.92E-09 | 5 | APOA2,APOA4,APOB,APOC3,ICAM1 | |
| Hyperlipoproteinemia | Metabolic disease | 3.29E-08 | 4 | APOA2,APOA4,APOB,APOC3 | |
| ⁎COVID19 | Respiratory tract disease Viral disease |
0.00606 | 2 | CCL2,IL6 | |
| Lopinavir + Ritonavir (SetAnalyzer) | Inflammation | Pathology (process) | 1.74E-18 | 10 | CCL2,CCL3,CCL4,CXCL2,CXCL8,ICAM1,IL1B,IL6,TNF,TNFAIP3 |
| Brain Ischemia | Cardiovascular disease Nervous system disease |
8.69E-18 | 9 | CCL2,CCL3,CCL4,CXCL2,ICAM1,IL1B,IL6,NFKBIA,TNF | |
| Pneumonia | Respiratory tract disease | 1.31E-16 | 8 | CCL2,CCL3,CCL4,CXCL1,CXCL8,IL1B,IL6,TNF | |
| Immune System Diseases | Immune system disease | 2.73E-16 | 13 | CCL2,CCL3,CCL4,CXCL1,CXCL2,CXCL8,ICAM1,IL1B,IL6,NFKB2,NFKBIA,TNF,TNFAIP3 | |
| Reperfusion Injury | Cardiovascular disease Pathology (process) |
4.67E-16 | 9 | CCL2,CCL3,CXCL1,CXCL2,CXCL8,ICAM1,IL1B,IL6,TNF | |
| Vascular Diseases | Cardiovascular disease | 2.19E-15 | 12 | CCL2,CCL3,CCL4,CXCL1,CXCL2,CXCL8,ICAM1,IL1B,IL6,NFKBIA,TNF,TNFAIP3 | |
| Myocardial Ischemia | Cardiovascular disease | 1.01E-14 | 10 | CCL2,CCL3,CCL4,CXCL2,CXCL8|ICAM1,IL1B,IL6,NFKBIA,TNF | |
| Shock, Hemorrhagic | Pathology (process) | 3.34E-14 | 5 | CXCL1,CXCL2,ICAM1,IL6,TNF | |
| Hypersensitivity | Immune system disease | 1.62E-13 | 9 | CCL2,CCL3,CCL4,CXCL1,CXCL2,ICAM1,IL1B,IL6,TNF | |
| Glomerulonephritis | Urogenital disease (male and female) | 1.70E-12 | 7 | CCL2,CCL3,CCL4,CXCL8,IL1B,IL6,TNF | |
| COVID19⁎ | Respiratory tract disease Viral disease |
3.18e-12 | 5 | CCL2,CCL3,IL1B,IL6,TNF |
⁎
was not among the top 10 related diseases.